<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 7-year-old German Shepherd dog was referred for evaluation of severe nonregenerative <z:hpo ids='HP_0001903'>anemia</z:hpo> (PCV, 10%; reticulocyte fraction, 0.2%) </plain></SENT>
<SENT sid="1" pm="."><plain>Cytologic examination of a bone marrow aspirate indicated erythroid predominance and dyserythropoiesis, and a diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with erythroid predominance was made </plain></SENT>
<SENT sid="2" pm="."><plain>The dog was given a single blood transfusion and was treated with <z:chebi fb="0" ids="8382">prednisone</z:chebi> and recombinant human erythropoietin (EPO) </plain></SENT>
<SENT sid="3" pm="."><plain>Eight weeks later, <z:hpo ids='HP_0001903'>anemia</z:hpo> had resolved </plain></SENT>
<SENT sid="4" pm="."><plain>The dog remained clinically <z:mpath ids='MPATH_458'>normal</z:mpath> 30 months after treatment, with a PCV of 45% </plain></SENT>
<SENT sid="5" pm="."><plain>Results suggest that EPO may be useful in the treatment of dogs with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with erythroid predominance or <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Additional studies are required to confirm the benefit of EPO to manage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-associated <z:hpo ids='HP_0001903'>anemia</z:hpo> in dogs </plain></SENT>
</text></document>